Nature Communications (Oct 2019)

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer

  • Katherine A. Michaelis,
  • Mason A. Norgard,
  • Xinxia Zhu,
  • Peter R. Levasseur,
  • Shamilene Sivagnanam,
  • Shannon M. Liudahl,
  • Kevin G. Burfeind,
  • Brennan Olson,
  • Katherine R. Pelz,
  • Diana M. Angeles Ramos,
  • H. Carlo Maurer,
  • Kenneth P. Olive,
  • Lisa M. Coussens,
  • Terry K. Morgan,
  • Daniel L. Marks

DOI
https://doi.org/10.1038/s41467-019-12657-w
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 15

Abstract

Read online

In the treatment of pancreatic ductal adenocarcinoma (PDAC), comorbidities such as cachexia limit quality of life and survival. Here, the authors show TLR7/8 agonist R848 remodels host and tumour immune responses, promoting survival and attenuating cachexia in murine models of PDAC.